(Q33395047)

English

A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

pancreatic cancer

1 reference

based on heuristic

inferred from title

author name string

Ken Hirao

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hirofumi Kawamoto

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ichiro Sakakihara

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yasuhiro Noma

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Naoki Yamamoto

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ryo Harada

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Koichiro Tsutsumi

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Masakuni Fujii

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hironari Kato

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Naoko Kurihara

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Osamu Mizuno

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tsuneyoshi Ogawa

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Etsuji Ishida

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kazuhide Yamamoto

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

26 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

International Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

637-645

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0237-Z

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0237-Z

21 January 2018

Survival from cancer of the pancreas in England and Wales up to 2001.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0237-Z

21 January 2018

Survival from cancer of the pancreas in England and Wales up to 2001

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0237-Z

21 January 2018

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0237-Z

21 January 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0237-Z

21 January 2018

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0237-Z

21 January 2018

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0237-Z

21 January 2018

Phase I trial of gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0237-Z

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0237-Z

21 January 2018

Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0237-Z

21 January 2018

Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0237-Z

21 January 2018

A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity

1 reference

https://pubmed.ncbi.nlm.nih.gov/21519814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21519814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21519814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I studies with the novel nucleoside analog gemcitabine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21519814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21519814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21519814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10147-011-0237-Z

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33395047&oldid=2195319212"